Therefore, the refinement of the ELN risk stratification in PV currently represents an active area of research on MPNs with an aim to delineate PV patients at different risks of future thrombotic events; this approach may potentially offer more personalized therapeutic approaches. This evidence concerns the gene ELN and acquired polycythemia vera.